Modality
mRNA
MOA
BCL-2i
Target
PD-1
Pathway
Neuroinflam
HS
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
Aug 2019
→ Nov 2031
Phase 1Current
NCT04383072
1,468 pts·HS
2019-08→TBD·Recruiting
NCT04489644
305 pts·HS
2024-12→2031-11·Not yet recruiting
1,773 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-235.6y awayInterim· HS
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Recruit…
P1
Not yet…
Catalysts
Interim
2031-11-23 · 5.6y away
HS
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04383072 | Phase 1 | HS | Recruiting | 1468 | Safety |
| NCT04489644 | Phase 1 | HS | Not yet recr... | 305 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |